Bone markers predict survival in castration-resistant prostate cancer patients treated with docetaxel

• 作者: Fang-Ching Lee Hiroyoshi Suzuki Koji Kawamura Masashi Yano Naoto Kamiya Ryo Oka Shuichi Kamijima Takanobu Utsumi Takashi Imamoto Takumi Endo Tomohiko Ichikawa
• 来源期刊: 世界临床泌尿杂志
• 学科: 医学
• 关键词: Prostate cancer DOCETAXEL chemotherapy Carboxy-terminal PYRIDINOLINE CROSS-LINKED telopeptide parts of type-1 COLLAGEN Alkaline PHOSPHATASE PROGNOSTIC factor
• 年，卷（期）: 2014,（2）
• 页码范围: 139-143
• 页数: 5页
• 分类号: R

摘要

AIM:To investigate the relationship between clinicopathological features and bone turnover markers in castration-resistant prostate cancer(CRPC)patients treated with docetaxel.METHODS:Thirty-three patients were enrolled in this study.Serum levels of carboxyterminal cross-linked telopeptide of type 1 collagen generated by metalloproteinases(1CTP)and alkaline phosphatase(ALP)were measured at the start of docetaxel chemotherapy.We examined the relationship between clinicopathological features and serum levels of 1CTP and ALP levels in CRPC patients treated with docetaxel.RESULTS:For the total patient group,the mean±standard deviation(SD)values for docetaxel chemotherapy dose,dose intensity,dosage interval,and number of cycles were 59.3±10.6 mg/m^2,13.9±5.2 mg/m^2 per week,4.7±1.2 wk,and 11.2±7.4,respectively.Fourteen patients died from prostate cancer.Patients were divided into two groups according to mean+SD of serum 1CTP(8.2 ng/mL)and ALP(538.2 IU/L)levels at the start of docetaxel chemotherapy.Patients with lower levels of serum 1CTP and ALP had significantly better survivals than those with higher serum levels(P<0.05).CONCLUSION:Serum levels of 1CTP and ALP are predictors of survival in patients with CRPC who are treated with docetaxel.